NCT00062101View on ClinicalTrials.gov

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2006

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally (PO)

DRUG

celecoxib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00062101 - Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter